Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
and now a 27k buy, all within the space of half an hour.......always good to see bigger buys when the price drops. Happy to see people are still confident of the upside. Would be nice to see the price of gold turn blue today.
Reflecting over the weekend, it’s obvious that the drop in share price was overdone with market makers and scaremongers only increasing fear….
• Novacyt are still trading and working directly with 130+ countries (inc UK)
• Current law requires PCR tests to enter most countries as well as used on returns form “Red List” countries.
• Government advice is that all Care home staff have to be tested using PCR tests on a weekly basis. Novacyt were the chosen provider to trial the tests working alongside Queen Mary University.
• Dhsc contract only issue with PCR, could still use the LFT and other products that the company produces.
• Novacyt was and still is an international Diagnostics company, that isn’t solely reliant of covid to generate revenue.
• The addition of the LFT tests, helps to create a start to finish covid diagnostics programme which meets the needs of both public and private companies.
• 20+ jobs on the website alone, indicates more still to come (3 more were announced hours after the recent RNS)
• Huge array of products offered including Lamp Tests, Promate, VariPlex & Winterplex.
• Some of our biggest clients include Pfizer, United States Army & GSK.
• Variplex is one of the first (and only) products around that can identify new variants and mutations.
• Up to 80% margins on pcr tests results in high EBITDA, which if required can definitely be reduced and still make the company impressive margins.
• World re-known reputation due to the high (and consistent) quality of the products produced.
• Novacyt believe they are in the right, the government and ncyt wont want this hanging over there head so would expect a quick resolution
• Without the DHSC contract, the company is still generating 36.3m revenue a quarter with more contract wins expected.
• In February hosted a webinar on the role of ‘Diagnostics Testing and Sequencing” which was attended by UK scientific advisors as well as countries and specialists around the globe.
• Private market exposure only going to increase with current clients including Nationwide pathology & Wren Healthcare.
• Graham Mullis bought shares at £8.17, he will be looking to make money on his investment.
• Acquisition of IT-IS International, a profitable diagnostic instrument development and manufacturing company
• Offer tests for hundreds of other virus including Japanese Encephalitis Virus, Zika Virus and Dengue Virus (which was recently spotted that an order from India had just come in for)
• The company is debt free and is holding a large cash position
For myself and many others I would like the group to offer some further insight which may bring calm amongst the storm;
• Who we are working with Countries, airports, private companies.
• Reason for the high number of jobs and is it affected by the DHSC contract
• Potential contract wins (Private v Public) as stated in the most recent RNS
• Revised figure update
• DHSC issues and likely next steps and outcome
Another week and another write up. This week - Bioworld picking up on our new two gene test product. More exposure alongside other (and in most cases bigger) medical companies cannot be underestimated.
"Addresses the need of countries" - Perfectly sums up the company and the products it releases, we don't go for the same size fits all approach - we cater to the needs of our clients be that care homes / hospitals / countries. This is why we are staying ahead of the curve and our competitors.
https://www.bioworld.com/articles/497439-other-news-to-note-for-sept-4-2020
"Outbreaks of Covid-like illnesses in care homes are at their highest levels in a MONTH, Public Health England data shows"
Another write up about Novacyt and the recent tie up with care home testing in the UK. Hopefully we can help be the difference in keeping those most vulnerable safe during this time.
https://www.dailymail.co.uk/news/article-8556371/Care-home-outbreaks-Covid-like-illnesses-highest-month-PHE-data-shows.html
Nice little write up today by 'Kalkine Media', which sums up the recent rns perfectly. Despite the share price not reflecting this, it's important to keep in mind the facts and how much the mcap really is both now and in the future.
"On 13 July 2020, the company declared it trading results for the half year ending 30 June 2020. The company generated revenue of €72.4 million for the first half of the year, displaying a whooping jump of 900 per cent y-o-y (H1 2019: €7.2 million). The company successfully developed and launched the world's first molecular tests for COVID-19, resulting in the estimated EBITDA to be over €45 million. The cash position stood at €20 million on 30 June 2020 (H2 2019: €1.8 million), as a result of the investment in order to meet the continued demand for the COVID-19 test. The sales of the company in June 2020 depicted €25.4 million. The company became debt-free for the very first time."
https://kalkinemedia.com/uk/news/stock-market/latest-financial-highlights-of-3-stocks-rua-ncyt-and-med
News regarding additional tests being sent to Egypt is being picked up by overseas media outlets and not just this side of the water, added exposure from abroad can only highlight the strength of this company;
https://www.cnbcafrica.com/africa-press-office/2020/06/28/coronavirus-egypt-british-embassy-holds-virtual-healthcare-webinar-on-covid-19/
https://lomazoma.com/egypt-news/102367.html
Despite a drop in the share price, the product is still performing at 100% accuracy and more tests are needed around the world. Unfortunately quite a few shareholders appear to have been spooked as of late despite all the recent news and what is still to come;
PHE confirming 100% success rate
Product being sold to 130 Countries
Debt free with cash in the bank and more confirmed
2 New Products coming on board in the near future
Multiple directors buying shares
Germany one of the two biggest buyers - whose continual testing has proved worthwhile
Scaling up to 10 million tests a month from June with capacity to grow further
Daily cases now averaging at 110k with more testing needed
US update expected imminently
Same day shipping of tests
46+ New Staff Recruited
Communication from the company is definitely something that could be improved going forwards, yet the facts don't lie and the results (as promised) are encouraging.
- Working with 130 countries worldwide
- Biggest clients being the UK and Germany
- Orders coming in from both Africa / South America who only appear to be at the start of all this
- Mobile Testing / ExSig in the pipeline, and on schedule!
- Order book of £120 million compared to £12 million of revenues generated by the whole business in 2019
- US update expected imminently
Let the day traders clear out and then this will go up once more. The directors have been buying more shares themselves over the last few weeks, they know what is still to come.
Primer Design highlighting all the current (and ever-growing) job vacancy list on Novacyt's website. The company are now advertising for 18 jobs, both here in the UK and across the pond in the USA. 17 of these jobs relate to Primer Design themselves.
Growing demand = Increased Jobs
https://twitter.com/PrimerdesignLtd/status/1265957166395129862
https://novacyt.com/careers/
Would be great to see head count in the next rns and how many new staff have been taken on, to help highlight how this "little" company has transformed into one of the most important companies around at the moment.
https://www.theguardian.com/global-development/2020/may/21/egypt-doctors-ppe-testing-coronavirus
More good publicity for Primer Design and more international recognition, hopefully the collaboration with Egypt can be beneficial and we can continue to help and support our Egyptian friends and provide the much needed testing kits.
Egypt records highest daily rise of 720 new cases.............which also highlights the recent delivery of testing kits from Primer Design / Novacyt
ZAWYA.com, part of Refinitiv Middle East, is a leading source of regional news and intelligence, serving more than 1 million professionals with up-to-date business, financial markets and industry news.
https://www.zawya.com/mena/en/life/story/COVID19_Egypt_records_highest_daily_rise_of_720_new_cases-SNG_174983722/
With media coverage now picking up our Egypt partnership, here are some of the recent media outlets that have picked up our story:
Matt Han**** Speech - https://www.gov.uk/government/speeches/health-and-social-care-secretarys-statement-on-coronavirus-covid-19-1-may-2020
This is money - https://www.thisismoney.co.uk/money/markets/article-8320749/Covid-testing-kits-fuel-sales-boom-Novacyt.html
Harley Street Clinic Product Review - https://privateharleystreetclinic.com/products/covid-19-test
The Sunday Times - https://www.thetimes.co.uk/article/bumper-year-ahead-for-firm-selling-covid-tests-to-the-nhs-ld60bnmns
African News - https://www.africanews.com/2020/03/16/british-company-ramps-up-production-for-covid-19-test-kits//
Egypt Partnership - https://www.gov.uk/government/news/uk-company-delivers-over-40000-pcr-test-kits-to-egypt
4 jobs recently added to Total Jobs under the Novacyt brand, including one National Sales Manager - "Field Based in the USA (covering the United States and Canada)"
https://www.totaljobs.com/jobs-at/novacyt/jobs
Further expansion into North America is a promising sign and especially encouraging after Abbott's faulty test results. This is a prime time to move further into America / Canada."